Highlighted Papers
Vannam R, Sayilgan J, Ojeda S, Karakyriakou B, Hu E, Kreuzer J, Morris R, Herrera Lopez XI, Rai S, Haas W, Lawrence M, Ott CJ^.
Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Cell Chemical Biology, 2021
Featured by Meier et al. in Cell Chemical Biology
Ott CJ*^, Federation AJ*, Schwartz LS, Kasar S, Klitgaard JL, Lenci R, Li Q, Lawlor M, Fernandes SM, Souza A, Polaski D, Gadi D, Freedman ML, Brown JR^, Bradner JE^.
Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia.
Cancer Cell, 2018
Featured by Plass et al. in Cancer Cell
Shortt J*, Ott CJ*, Johnstone R^, Bradner JE^.
A chemical probe toolbox for dissecting the cancer epigenome.
Nature Reviews Cancer, 2017
Team members in bold
* equal contribution
^ corresponding author
Complete published work
Tiwari PK*, Doda SR*, Vannam R*, Hudlikar M*, Harrison DA, Ojeda S, Rai S, Koglin A-S, Gilbert AN, Ott CJ^.
Exploration of bromodomain ligand-linker conjugation sites for efficient CBP/p300 heterobifunctional degrader activity.
Bioorganic & Medicinal Chemistry Letters, 2024
Bakaric A, Cironi L, Praz V, Sanalkumar R, Broye LC, Favre-Bulle K, Letovanec I, Digklia A, Renella R, Stamenkovic I, Ott CJ, Nakamura T, Antonescu CR, Rivera MN, Riggi N^.
CIC-DUX4 chromatin profiling reveals new epigenetic dependencies and actionable therapeutic targets in CIC-rearranged sarcomas.
Cancers (Basel), 2024
Zhang Y, Remillard D, Onubogu U, Karakyriakou B, Asiaban JN, Ramos AR, Bowland K, Bishop TR, Barta PA, Nance S, Durbin AD, Ott CJ, Janiszewska M, Cravatt BF, Erb MA^.
Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities.
Nature Structural & Molecular Biology, 2023
Isozaki H^, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, Langenbucher A, Monroe S, Su W, Cabanos HF, Siddiqui FM, Phan N, Jalili P, Timonina D, Bilton S, Gomez-Caraballo M, Archibald HL, Nangia V, Dionne K, Riley A, Lawlor M, Banwait MK, Cobb RG, Zou L, Dyson NJ, Ott CJ, Benes C, Getz G, Chan CS, Shaw AT, Gainor JF, Lin JJ, Sequist LV, Piotrowska Z, Yeap BY, Engelman JA, Lee JJ, Maruvka YE, Buisson R, Lawrence MS^, Hata AN^.
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Nature, 2023
de Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL, Matthews GM, Barwick BG, Gupta VA, Dupéré-Richer D, Yamano S, Hu Y, Sheffer M, Dhimolea E, Dashevsky O, Gandolfi S, Ishiguro K, Meyers RM, Bryan JG, Dharia NV, Hengeveld PJ, Brüggenthies JB, Tang H, Aguirre AJ, Sievers QL, Ebert BL, Glassner BJ, Ott CJ, Bradner JE, Kwiatkowski NP, Auclair D, Levy J, Keats JJ, Groen RWJ, Gray NS, Culhane AC, McFarland JM, Dempster JM, Licht JD, Boise LH, Hahn WC, Vazquez F^, Tsherniak A^, Mitsiades CS^.
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.
Nature Cancer, 2023
Bishop TR, Subramanian C, Bilotta EM, Garnar-Wortzel L, Ramos AR, Zhang Y, Asiaban JN, Ott CJ, Rock CO, Erb MA^.
Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition.
Nature Chemical Biology, 2023
Gill T, Wang H, Bandaru R, Lawlor M, Lu C, Nieman LT, Tao J, Zhang Y, Anderson DG, Ting DT, Chen X, Bradner JE^, Ott CJ^.
Selective targeting of MYC mRNA by stabilized antisense oligonucleotides.
Oncogene, 2021
Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T, DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, Reich TJ, Bhoj VG, Haines KM, Maus MV, Melenhorst JJ, Young RM, Jadlowsky JK, Marchucci KT, Bradner JE, Levine BL, Porter DL, Bushman FD, Kohli RM, June CH, Davis MM, Lacey SF, Vahedi G, Fraietta JA^.
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
Journal of Clinical Investigation, 2021
Willers H^, Pan X, Borgeaud N, Korovina I, Koi L, Egan R, Greninger P, Rosenkranz A, Kung J, Liss AS, Parsels LA, Morgan MA, Lawrence TS, Lin SH, Hong TS, Yeap BY, Wirth L, Hata AN, Ott CJ, Benes CH, Baumann M, Krause M.
Screening and validation of molecular targeted radiosensitizers.
International Journal of Radiation Oncology*Biology*Physics, 2021
Lazarian G*, Yin S*, ten Hacken E*, Sewastianik T, Uduman M, Font-Tello A, Gohil SH, Li S, Kim E, Joyal H, Billington L, Witten E, Zheng M, Huang T, Severgnini M, Lefebvre V, Rassenti LZ, Gutierrez C, Georgopoulos K, Ott CJ, Wang L, Kipps TJ, Burger JA, Livak KJ, Neuberg DS, Baran-Marszak F, Cymbalista F, Carrasco RD, Wu CJ^.
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation.
Cancer Cell, 2021
Koduri V*, Duplaquet L*, Lampson BL, Wang AC, Sabet AH, Ishoey M, Paulk J, Teng M, Harris IS, Endress JE, Liu X, Dasilva E, Paulo JA, Briggs KJ, Doench JG, Ott CJ, Zhang T, Donovan KA, Fischer ES, Gygi SP, Gray NS, Bradner J, Medin JA, Buhrlage SJ, Oser MG^, Kaelin WG Jr^.
Targeting oncoproteins with a positive selection assay for protein degraders.
Science Advances, 2021
Shirasaki R, Matthews GM, Gandolfi S, de Matos Simoes R, Buckley DL, Raja Vora J, Sievers QL, Brüggenthies JB, Dashevsky O, Poarch H, Tang H, Bariteau MA, Sheffer M, Hu Y, Downey-Kopyscinski SL, Hengeveld PJ, Glassner BJ, Dhimolea E, Ott CJ, Zhang T, Kwiatkowski NP, Laubach JP, Schlossman RL, Richardson PG, Culhane AC, Groen RWJ, Fischer ES, Vazquez F, Tsherniak A, Hahn WC, Levy J, Auclair D, Licht JD, Keats JJ, Boise LH, Ebert BL, Bradner JE, Gray NS, Mitsiades CS^.
Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins.
Cell Reports, 2021
Vannam R, Sayilgan J, Ojeda S, Karakyriakou B, Hu E, Kreuzer J, Morris R, Herrera Lopez XI, Rai S, Haas W, Lawrence M, Ott CJ^.
Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Cell Chemical Biology, 2021
Ott CJ^.
Circles with a point: new insights into oncogenic extrachromosomal DNA.
Cancer Cell, 2020
Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ^.
Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies.
Cancer Cell, 2019
Viny AD, Bowman RL, Liu Y, Lavallée VP, Eisman SE, Xiao W, Durham BH, Navitski A, Park J, Braunstein S, Alija B, Karzai A, Csete IS, Witkin M, Azizi E, Baslan T, Ott CJ, Pe'er D, Dekker J, Koche R, Levine RL^.
Cohesin members Stag1 and Stag2 display distinct roles in chromatin accessibility and topological control of HSC self-renewal and differentiation.
Cell Stem Cell, 2019
Sharifnia T^, Wawer MJ, Chen T, Huang QY, Weir BA, Sizemore A, Lawlor MA, Goodale A, Cowley GS, Vazquez F, Ott CJ, Francis JM, Sassi S, Cogswell P, Sheppard HE, Zhang T, Gray NS, Clarke PA, Blagg J, Workman P, Sommer J, Hornicek F, Root DE, Hahn WC, Bradner JE, Wong KK, Clemons PA, Lin CY^, Kotz JD^, Schreiber SL^.
Small-molecule targeting of brachyury transcription factor addiction in chordoma.
Nature Medicine, 2019
Ott CJ*^, Federation AJ*, Schwartz LS, Kasar S, Klitgaard JL, Lenci R, Li Q, Lawlor M, Fernandes SM, Souza A, Polaski D, Gadi D, Freedman ML, Brown JR^, Bradner JE^.
Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia.
Cancer Cell, 2018
Fulciniti M*, Lin CY*, Samur MK, Lopez MA, Singh I, Lawlor MA, Szalat RE, Ott CJ, Avet-Loiseau H, Anderson KC, Young RA, Bradner JE, Munshi NC^.
Non-overlapping control of transcriptome by promoter- and super-enhancer-associated dependencies in multiple myeloma.
Cell Reports, 2018
Peeken JC, Jutzi JS, Wehrle J, Koellerer C, Staehle HF, Becker H, Schoenwandt E, Seeger TS, Schanne DH, Gothwal M, Ott CJ, Gründer A, Pahl HL^.
Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms.
Blood, 2018
Gechijian LN*, Buckely DL*, Lawlor MA, Reyes JM, Paulk J, Ott CJ, Winter GE, Erb MA, Scott TG, Xu M, Seo HS, Dhe-Paganon S, Kwiatkowski NP, Perry JA, Qi J, Gray NS^, Bradner JE^.
Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands.
Nature Chemical Biology, 2018
Ott CJ, Wu CJ^.
HDAC inhibitors finally open up: chromatin accessibility signatures of CTCL.
Cancer Cell, 2017
Winter GE*, Mayer A*, Buckley DL*, Erb MA*, Roderick JE, Vittori S, Reyes JM, di Iulio J, Souza A, Ott CJ, Roberts JM, Zeid R, Scott TG, Paulk J, Lachance K, Olson CM, Dastjerdi S, Bauer S, Lin CY, Gray NS, Kelliher MA, Churchman LS^, Bradner JE^.
BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment.
Molecular Cell, 2017
Shortt J*, Ott CJ*, Johnstone R^, Bradner JE^.
A chemical probe toolbox for dissecting the cancer epigenome.
Nature Reviews Cancer, 2017
Ott CJ^.
Opportunities for targeting gene regulatory factors in B-cell acute lymphoblastic leukemia.
International Journal of Hematologic Oncology, 2017
Hogg SJ*, Vervoot SJ*, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, Traunbauer AK, Sadovnik I, Bauer K, Valent P, Bradner JE, Zuber J, Shortt J^, Johnstone RW^.
BET-Bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1.
Cell Reports, 2017
Koblan LW*, Buckley DL*, Ott CJ*, Fitzgerald ME*, Ember S, Zhu J-Y, Lui S, Roberts JM, Remillard D, Vittori S, Zhang W, Schonbrunn E, Bradner JE^.
Assessment of bromodomain target engagement by a series of BI2536 analogues with miniaturized BET-BRET.
ChemMedChem, 2016
Yang S, Ott CJ, Rossmann MP, Superdock M, Zon LI, Zhou Y^.
Chromatin immunoprecipitation and an open chromatin assay in zebrafish erythrocytes.
Methods Cell Biology, 2016
Koo SJ^, Fernández-Montalván AE, Badock V, Ott CJ, Holton SJ, von Ahsen O, Toedling J, Vittori S, Bradner JE, Gorjánácz M^.
ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication.
Oncotarget, 2016
Shu S*, Lin CY*, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer EP, Letai A, Barry WT, Carroll JS, Long HW, Brown M, Liu XS, Meyer CA, Bradner JE^, Polyak K^.
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Nature, 2016
Viny AD*, Ott CJ*, Spitzer B, Rivas M, Meydan C, Paplexi E, Yelin D, Shank K, Reyes J, Chiu A, Romin Y, Boyko V, Thota S, Maciejewski JP, Melnick A, Bradner JE^, Levine RL^.
Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis.
Journal of Experimental Medicine, 2015
Knoechel B*, Roderick JE*, Williamson KE, Zhu J, Lohr JG, Cotton MG, Gillespie SM, Fernandez D, Ku M, Wang H, Piccioni F, Silver SJ, Jain M, Pearson D, Kluk MJ, Ott CJ, Shultz LD, Brehm MA, Greiner DL, Gutierrez A, Stegmaier K, Kung AL, Root DE, Bradner JE, Aster JC, Kelliher MA^, Bernstein BE^.
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
Nature Genetics, 2014
Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr^.
The myeloma drug lenalidomide promotes cereblon-dependent destruction of Ikaros proteins.
Science, 2014
Ott CJ^.
Promising new strategies to target gene regulatory factors in T-cell acute lymphoblastic leukemia. International Journal of Hematologic Oncology, 2014
Yigit E, Bischof JM, Zhang Z, Ott CJ, Kerschner JL, Leir S-H, Buitrago-Delgado E, Zhang Q, Wang JP, Widom J, Harris A^.
Nucleosome mapping across the CFTR locus identifies novel regulatory factors.
Nucleic Acids Research, 2013
Ott CJ*, Kopp N*, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung KL, Bradner JE^, Weinstock DM^.
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Blood, 2012
Bischof JM, Ott CJ, Leir S-H, Gosalia N, Cotton CU, Crawford GE, Harris A^.
A genome-wide analysis of open chromatin in human tracheal epithelial cells reveals novel candidate regulatory elements for lung function.
Thorax, 2012
Ott CJ, Bischof JM, Unti KM, Gillen AE, Leir S-H, Harris A^.
Nucleosome occupancy reveals regulatory elements of the CFTR promoter.
Nucleic Acids Research, 2012
Zhang Z, Ott CJ, Lewandowska MA, Costa FF, Leir S-H, Bischof JM, Soares MB, Harris A^.
Molecular mechanisms controlling CFTR gene expression in the airway.
Journal of Cellular and Molecular Medicine, 2012
Ott CJ, Harris A^.
Genomic approaches for the discovery of CFTR regulatory elements.
Transcription, 2011
Ott CJ, Harris A^.
Genomic approaches to studying CFTR transcriptional regulation.
Methods in Molecular Medicine: Cystic Fibrosis Protocols and Diagnosis, 2011
Ott CJ, Blackledge NP, Kerschner JL, Leir S-H, Crawford GE, Cotton CU, Harris A^.
Intronic enhancers coordinate epithelial-specific looping of the active CFTR locus.
Proceedings of the National Academy of Sciences, 2009
McCarthy VA, Ott CJ, Phylactides M, Harris A^.
Interaction of intestinal and pancreatic transcription factors in the regulation of CFTR gene expression.
Biochimica et Biophysica Acta, 2009
Ott CJ, Suszko M, Blackledge NP, Wright JE, Crawford GE, Harris A^.
A complex intronic enhancer regulates expression of the CFTR gene by direct interaction with the promoter.
Journal of Cellular and Molecular Medicine, 2009
Ott CJ, Blackledge NP, Leir S-H, Harris A^.
Novel regulatory mechanisms for the CFTR gene.
Biochemical Society Transactions, 2009
Chen Y, Ott CJ, Townsend K, Subbaiah P, Aiyar A, Miller WM^.
Cholesterol supplementation during production increases the infectivity of retroviral and lentiviral vectors pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G).
Biochemical Engineering Journal, 2009
Blackledge NP, Ott CJ, Gillen A, Harris A^.
An insulator element 3' to the CFTR gene binds CTCF and reveals an active chromatin hub in primary cells. Nucleic Acids Research, 2009
Elkahwaji JE, Ott CJ, Janda LM, Hopkins WJ^.
Mouse model for acute bacterial prostatitis in genetically distinct inbred strains.
Urology, 2005
Sears J, Ujihara M, Wong S, Ott C, Middledorp J, Aiyar A^.
EBNA1 binds chromosomes using amino-terminal AT-hooks.
Journal of Virology, 2004
Hopkins WJ^, Elkahwaji JE, Heisey DM, Ott CJ.
Inheritance of susceptibility to induced Escherichia coli bladder and kidney infections in female C3H/HeJ mice.
Journal of Infectious Diseases, 2003